Efficacy and safety of firocoxib in the management of canine osteoarthritis under field conditions

Autor: Peter D, Hanson, Kenneth C, Brooks, Jerry, Case, Michael, Conzemius, Wanda, Gordon, James, Schuessler, Bert, Shelley, Roger, Sifferman, Marlene, Drag, Roberto, Alva, Laura, Bell, Davida, Romano, Candis, Fleishman
Rok vydání: 2006
Předmět:
Zdroj: Veterinary therapeutics : research in applied veterinary medicine. 7(2)
ISSN: 1528-3593
Popis: A total of 249 client-owned dogs with osteoarthritis were treated with firocoxib (5 mg/kg/day) or a positive control, etodolac (10-15 mg/kg/day), for 30 days. Veterinary examinations were performed on approximately days 0 (visit 1), 14 (visit 2), and 29 (visit 3). Based on defined noninferiority criteria, firocoxib and etodolac were comparable. Based on the magnitude of the change from baseline, improvement with firocoxib was significantly greater than with etodolac for lameness at a trot (visits 2 and 3) and for lameness at a walk, pain on manipulation, and range of motion (visit 3) (P.05). In weekly owner evaluations, firocoxib provided significantly greater improvement than etodolac (P.05) at each scoring.
Databáze: OpenAIRE